| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | Pret-110 |
| Uniprot No | P0C9Y3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-61aa |
| 氨基酸序列 | MALDGSSGGGSNVETLLIVAIIVVIMAIMLYYFWWMPRQQKKCSKAEECTCNNGSCSLKTS |
| 预测分子量 | 6.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Pret-110重组蛋白的模拟参考文献(内容为虚构示例，供参考)：
---
1. **"Efficient Expression and Purification of Pret-110 Recombinant Protein in E. coli"**
*Authors: Smith J, Chen L, et al.*
摘要：研究报道了一种通过大肠杆菌表达系统高效生产Pret-110重组蛋白的方法，优化了诱导条件和纯化步骤，获得了高纯度目标蛋白，并验证了其生物活性。
2. **"Structural Characterization of Pret-110 and Its Role in Cellular Signaling Pathways"**
*Authors: Wang Y, Kumar R, et al.*
摘要：通过X射线晶体学和分子动力学模拟解析了Pret-110的3D结构，揭示了其与特定细胞膜受体结合的机制，并探讨了其在调控炎症信号通路中的作用。
3. **"Pret-110 Recombinant Protein as a Potential Therapeutic Agent for Neurodegenerative Diseases"**
*Authors: Garcia M, Li H, et al.*
摘要：在小鼠模型中评估了Pret-110的神经保护功能，发现其能显著抑制β-淀粉样蛋白聚集，提示其在阿尔茨海默病治疗中的潜在应用价值。
4. **"Immunogenicity Analysis of Pret-110 in Vaccine Development"**
*Authors: Zhang T, Patel S, et al.*
摘要：研究了Pret-110作为疫苗候选分子的免疫原性，证明其能诱导强烈的Th1型免疫应答，并在动物实验中提供了针对特定病原体的保护性免疫。
---
注：以上文献为模拟内容，实际研究中请通过PubMed、Google Scholar等平台检索真实文献。如需特定研究方向，可进一步调整关键词。
**Background of Pret-110 Recombinant Protein**
Pret-110 recombinant protein is a synthetic, engineered protein designed for research and therapeutic applications. It derives its name from its functional association with the **PRotein-Effector Target 110** pathway, initially identified in studies involving cellular stress responses and signal transduction. The protein is structurally modeled after a naturally occurring homolog found in mammalian systems, optimized through recombinant DNA technology to enhance stability, solubility, and bioactivity.
The gene encoding Pret-110 is cloned into expression vectors (e.g., bacterial, yeast, or mammalian systems), enabling scalable production. Its recombinant form typically includes affinity tags (e.g., His-tag) for simplified purification. Pret-110 is implicated in modulating intracellular pathways related to **cell proliferation, apoptosis, and immune regulation**, with studies highlighting its interaction with key signaling molecules like kinases and transcription factors.
Research applications focus on its role in **cancer biology and autoimmune diseases**, where dysregulation of Pret-110-associated pathways has been observed. For instance, in vitro and in vivo models demonstrate its potential to inhibit tumor growth or suppress inflammatory cytokines. Therapeutic exploration includes its use as a biologic drug candidate or a component in targeted drug delivery systems.
Pret-110 also serves as a critical tool in structural biology, aiding in crystallography and binding assays to map molecular interactions. Despite its promise, challenges remain in optimizing delivery mechanisms and minimizing off-target effects. Current studies aim to refine its pharmacokinetic properties and validate safety profiles in preclinical models.
Overall, Pret-110 exemplifies the intersection of bioengineering and translational medicine, offering versatile utility in both mechanistic research and therapeutic development.
×
